SCHEMBL16067665

SCHEMBL16067665

c1ccc(-c2ccc(-c3c4ccccc4c(-c4cccc(-c5ccc6oc7c8ccccc8c8ccccc8c7c6c5)c4)c4ccccc34)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 5/20 0.43
PLA2G4A P47712 5/20 0.43
PLA2G10 O15496 1/20 0.43
PRKDC P78527 3/20 0.38
GAA P10253 3/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CYP3A4 P08684 1/20 0.36
ALPI P09923 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
CASP3 P42574 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
CASP7 P55210 1/20 0.36
CASP6 P55212 1/20 0.36
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16067663 0.99 PLA2G2A (0.44) PLA2G2APLA2G4APLA2G10PRKDCGAA
SCHEMBL16067664 0.99 PLA2G2A (0.44) PLA2G2APLA2G4APLA2G10PRKDCGAA
SCHEMBL16067793 0.99 PLA2G2A (0.44) PLA2G2APLA2G4APLA2G10PRKDCGAA
SCHEMBL17944462 0.96 PLA2G2A (0.44) PLA2G2APLA2G4APLA2G10PRKDCGAA
SCHEMBL16067790 0.96 PLA2G2A (0.41) PLA2G2APLA2G4APLA2G10GAAKDM4E
SCHEMBL16067589 0.94 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10GAAKDM4E
SCHEMBL23502244 0.92 PLA2G2A (0.41) PLA2G2APLA2G4APLA2G10PRKDCGAA
SCHEMBL19108680 0.92 PLA2G2A (0.44) PLA2G2APLA2G4APLA2G10PRKDCGAA
SCHEMBL20053372 0.92 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10PRKDCGAA
SCHEMBL23502157 0.92 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10PRKDCGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180208836-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-07-26 US disclosed
US-20180208836-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-07-26 US disclosed
US-20180198077-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2018-07-12 US disclosed
US-20180198077-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2018-07-12 US disclosed
US-20180130968-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-05-10 US disclosed
US-20180130968-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-05-10 US disclosed
US-9947879-B2 Anthracene derivative and organic electroluminescence element using same IDEMITSU KOSAN CO., LTD. (JP) 2018-04-17 US disclosed
US-9947879-B2 Anthracene derivative and organic electroluminescence element using same IDEMITSU KOSAN CO., LTD. (JP) 2018-04-17 US disclosed
US-20150325800-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2015-11-12 US disclosed
US-20150325800-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2015-11-12 US disclosed
EP-2924029-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME Idemitsu Kosan Co., Ltd (JP) 2015-09-30 EP disclosed
WO-2014141725-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME 出光興産株式会社 (JP) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180130968-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE RER1, NR0B1, NR2E1 PLA2G2A 2960/4885PLA2G4A 3780/4885PLA2G10 4476/4885
US-20180198077-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME ANXA1, ANXA11, L1CAM PLA2G2A 1281/4885PLA2G4A 1656/4885PLA2G10 1522/4885
US-20150325800-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME ANXA1, ANXA11, L1CAM PLA2G2A 1281/4885PLA2G4A 1656/4885PLA2G10 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.